NFKB1 and atherosclerosis: miR520c-3p inhibits the PDGF-BB-mediated proliferation and migration of human aortic SMCs by targeting the RelA/p65 NF-κB signaling pathway, providing potential therapeutic strategies in atherosclerosis treatment; and the miR520c-3p agomir also decreases serum TG levels by an unknown mechanism (Figure 2e) [51].